Merck KGAA Courts US, China Investors To Accelerate Immuno-Oncology Development
Executive Summary
EMD Serono Inc.'s Head of BioPharma External Innovation Ravi Kiron outlines to Brian Yang how the Merck KGAA Group is courting US and Chinese Investors to fund such projects with a size of $100-200m.